Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Soligenix's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-2.83 Mil. Soligenix's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Soligenix's pretax margin for the quarter that ended in Mar. 2026 was %.
The historical rank and industry rank for Soligenix's Pretax Margin % or its related term are showing as below:
LTS:0A6I's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.37 * Ranked among companies with meaningful Pretax Margin % only.
Soligenix (LTS:0A6I) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Soligenix Pretax Margin % Related Terms
Soligenix Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Soligenix's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0A6I vs APVO, BCAB, RNAZ: Pretax Margin % Comparison
For the Biotechnology subindustry, Soligenix's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soligenix Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soligenix's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Soligenix's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soligenix (LTS:0A6I) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Soligenix and its competitors. According to the industry distribution chart, Soligenix ranks #999999 out of 941 companies in the Biotechnology industry.
Is Soligenix's Pretax Margin % too high?
Soligenix's current Pretax Margin % is %. Based on the distribution chart, Soligenix ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Soligenix has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Soligenix's Pretax Margin % compare to APVO and BCAB?
According to the Biotechnology industry distribution chart, Soligenix ranks #999999 out of 941 companies for Pretax Margin %. This places Soligenix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Soligenix and its competitors. Soligenix's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soligenix stock overvalued right now?
Based on GuruFocus' analysis, Soligenix (LTS:0A6I) is currently considered Possible Value Trap. The stock's GF Value™ is $3.61, compared to a current price of $0.36 — trading 90% below its estimated fair value. The current Pretax Margin % is %. Soligenix's overall GF Score™ is 41/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Soligenix (LTS:0A6I), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Soligenix (LTS:0A6I) Overvalued in 2026?
Based on GuruFocus' analysis, Soligenix stock appears to be undervalued.
The current stock price of $0.36 is trading 90% below its estimated GF Value™ of $3.61.
GuruFocus considers Soligenix to be Possible Value Trap.
Key valuation signals for LTS:0A6I:
Pretax Margin %: %
GF Value™: $3.61 vs. price of $0.36 (90% below fair value)
No single metric tells the full story. See the LTS:0A6I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
41GF Score
Get the complete analysis for LTS:0A6I
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0A6I has been successfully added to your 
